secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001628280-26-031241
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q1 net loss widens to $0.82/share; raises FY2026 revenue guidance on NEREUS launch
--------------------------------------------------------------------------------

- Fanapt net product sales $29.6M (+26% YoY); total prescriptions +32%, new-to-brand +76%.
- NEREUS (tradipitant) launched via direct-to-consumer platform; first new motion sickness drug in 40+ years.
- FY2026 revenue guidance raised to $240-290M from $230-260M, including $10-30M from NEREUS.
- Net loss $48.6M ($0.82 diluted EPS) vs loss $29.5M ($0.50) in Q1 2025.
- BYSANTI (milsaperidone) received FDA approval Feb 20 for bipolar I and schizophrenia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-031241

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer